bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
8.35
+0.09 (1.09%)
Jan 17, 2025, 4:00 PM EST - Market closed
bluebird bio Stock Forecast
BLUE's stock price has decreased by -70.8% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for bluebird bio stock have an average target of 49.14, with a low estimate of 10 and a high estimate of 120. The average target predicts an increase of 488.50% from the current stock price of 8.35.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for bluebird bio stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $2 → $40 | Buy | Maintains | $2 → $40 | +379.04% | Dec 31, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $80 | Hold | Reiterates | $80 | +858.08% | Nov 15, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $60 → $10 | Strong Buy → Hold | Downgrades | $60 → $10 | +19.76% | Nov 15, 2024 |
| Barclays | Barclays | Buy Maintains $80 → $40 | Buy | Maintains | $80 → $40 | +379.04% | Nov 15, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $60 → $40 | Hold | Maintains | $60 → $40 | +379.04% | Sep 25, 2024 |
Financial Forecast
Revenue This Year
72.53M
from 29.50M
Increased by 145.88%
Revenue Next Year
246.51M
from 72.53M
Increased by 239.89%
EPS This Year
-27.77
from -38.60
EPS Next Year
-8.82
from -27.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 79.5M | 403.0M | 434.7M | |||
| Avg | 72.5M | 246.5M | 316.9M | |||
| Low | 62.0M | 143.0M | 239.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 169.5% | 455.6% | 76.3% | |||
| Avg | 145.9% | 239.9% | 28.6% | |||
| Low | 110.3% | 97.1% | -3.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -25.41 | 2.73 | -10.92 | |||
| Avg | -27.77 | -8.82 | -14.48 | |||
| Low | -28.86 | -23.13 | -17.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.